FIELD: chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to a method for preparing S-adenosylmethionine containing tablets. Method involves mixing S-adenosylmethionine and/or its salt with sulfuric and/or para-toluenesulfonic acid with calcium sulfate and/or phosphate, calcium and/or magnesium carbonate, glycerol bigenate and/or palmitostearate and silicon dioxide followed by pressing and applying a cover. Tablets prepared by this method show low relative moisture and hygroscopicity and high stability under condition of air exposition.
EFFECT: improved preparing method of tablet.
10 cl, 79 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| S-ADENOSYLMETHIONINE COMPOSITIONS FOR PERORAL APPLICATION | 2006 |
|
RU2427376C2 |
| PHARMACEUTICAL MICROSPHERICAL VALPROIC ACID PARTICLE FOR ORAL ADMINISTRATION | 1997 |
|
RU2177315C2 |
| SOLID TABLETS AND CAPSULES OF MODIFIED RELEASE OF BENZONATATE | 2014 |
|
RU2673239C2 |
| DELAYED DOSAGE FORM FOR TREATING INSOMNIA | 2005 |
|
RU2458685C2 |
| EXTRUDATES WITH NEEDLE-LIKE ACTING SUBSTANCES | 2009 |
|
RU2549450C2 |
| DISPERSED TABLETS DEFERASIROKS | 2003 |
|
RU2338532C2 |
| PHARMACEUTICAL COMPOSITION OF METFORMIN WITH PROLONGED RELEASE AND METHOD OF ITS OBTAINING | 2006 |
|
RU2433821C2 |
| SLOW-RELEASE TABLET WITH SPECIFIED CORE GEOMETRY | 2004 |
|
RU2391093C2 |
| CRYSTALLINE FORMS OF 1-(3-TRET-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETIL)-1H-INDASOL-5-YLOXY)BENZYL) HYDROCHLORIDE UREA | 2013 |
|
RU2627702C2 |
| LIQUID ORAL DOSAGE FORM COMPOSITION OF METHYLNALTREXONE | 2020 |
|
RU2827066C2 |
